Cambrex Corporation (N:CBM)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 1 Meadowlands Plz
E RUTHERFORD NJ 07073-2150
Tel: 1-201-8043037
IR: See website
Key People
Steven Mark Klosk
President, Chief Executive Officer, Director
Gregory P. Sargen
Chief Financial Officer, Executive Vice President, Corporate Development and Strategy
Shawn P. Cavanagh
Chief Operating Officer, Executive Vice President
Dottie Donnelly Brienza
Chief Human Resource Officer, Senior Vice President
Samantha M. Hanley
Vice President, General Counsel,Corporate Secretary
James G. Farrell
Vice President and Corporate Controller
Business Overview
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Financial Overview
For the nine months ended 30 September 2019, Cambrex Corporation revenues increased 22% to $484.9M. Net income before extraordinary items decreased 62% to $34.6M. Revenues reflect North America segment increase from $127.3M to $261M, Asia segment increase of 53% to $17.2M. Net income was offset by Other Selling, General and admin Exp increase of 66% to $72.7M (expense).
Employees: 1,732 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $2,431M as of Sep 30, 2019
Annual revenue (TTM): $619.20M as of Sep 30, 2019
EBITDA (TTM): $162.57M as of Sep 30, 2019
Net annual income (TTM): $36.02M as of Sep 30, 2019
Free cash flow (TTM): $65.83M as of Sep 30, 2019
Net Debt Last Fiscal Year: $413.61M as of Sep 30, 2019
Shares outstanding: 33,724,367 as of Sep 30, 2019
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization